$AZN Market Cap:
Research Board Inbox Deep Research Not Interested Shortlisted

$AZN SEC Filings

Filing Filed On
DIRECTOR DECLARATION 03 Oct 2019
UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD 01 Oct 2019
ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR 01 Oct 2019
TOTAL VOTING RIGHTS 01 Oct 2019
LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS 30 Sep 2019
LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN 30 Sep 2019
TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN 30 Sep 2019
QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP 23 Sep 2019
ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA 18 Sep 2019
IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP 09 Sep 2019
TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE 04 Sep 2019
BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART 03 Sep 2019
DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC 03 Sep 2019
TOTAL VOTING RIGHTS 03 Sep 2019
ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS 29 Aug 2019
FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS 28 Aug 2019
BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS 28 Aug 2019
ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW 22 Aug 2019
ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND 22 Aug 2019
UPDATE ON THE PHASE III NEPTUNE TRIAL 21 Aug 2019